Literature DB >> 31242292

CD166high Uveal Melanoma Cells Represent a Subpopulation With Enhanced Migratory Capacity.

Luna Djirackor1,2, Helen Kalirai1, Sarah E Coupland1, Goran Petrovski2,3.   

Abstract

Purpose: Cancer stem cells (CSCs) are a subpopulation of cells with the capacity to drive tumor growth. While there is evidence of the existence of CSCs in uveal melanoma (UM), there is no consensus on their defining markers. In this study, we examined putative CSC markers in UM cell lines, primary UM (PUM), and normal choroidal melanocytes (NCM).
Methods: Nonadherent sphere assays were used to assess the tumorigenic potential of 15 PUMs, 8 high (M3) and 7 low (D3) metastatic risk. Flow cytometry was used to compare the expression of CSC markers between 10 PUMs and 4 NCMs, as well as in 8 UM cell lines grown under adherent and nonadherent conditions. Based on the data generated and from TCGA analyses, CD166 was investigated in detail, including its effect on cell migration using a tumor transendothelial migration assay.
Results: M3 PUM had a greater melanosphere-forming efficiency than D3 PUM. CD166 and Nestin expression was upregulated in PUM compared to NCM by flow cytometry. UM cell lines resistant to anoikis had increased levels of CD271, Nestin, and CD166 compared with adherent cells. TCGA analysis showed that patients with higher CD166 expression had a poorer prognosis: this was supported by a Mel270 CD166high subpopulation that had enhanced migratory capabilities compared with CD166low cells. IHC showed that CD166 is expressed in the cytoplasm and cell membrane of PUM cells. Conclusions: UM contain a population of cells with characteristics of CSCs. In particular, CD166high UM cells appear to represent a subpopulation with enhanced migratory capacity.

Entities:  

Year:  2019        PMID: 31242292     DOI: 10.1167/iovs.18-26431

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.

Authors:  Ewelina Dratkiewicz; Aleksandra Simiczyjew; Katarzyna Pietraszek-Gremplewicz; Justyna Mazurkiewicz; Dorota Nowak
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

Review 2.  Research Progress of Cancer Stem Cells in Uveal Melanoma.

Authors:  Yu Ning Chen; Yang Li; Wen Bin Wei
Journal:  Onco Targets Ther       Date:  2020-11-27       Impact factor: 4.147

Review 3.  Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Authors:  Nuno Jorge Lamas; Arnaud Martel; Sacha Nahon-Estève; Samantha Goffinet; Adam Macocco; Corine Bertolotto; Sandra Lassalle; Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-12-25       Impact factor: 6.639

Review 4.  Scientific and clinical implications of genetic and cellular heterogeneity in uveal melanoma.

Authors:  Mark J de Lange; Rogier J Nell; Pieter A van der Velden
Journal:  Mol Biomed       Date:  2021-08-20

5.  Biological characteristics of endometriotic mesenchymal stem cells isolated from ectopic lesions of patients with endometriosis.

Authors:  Yanli Liu; Shengying Liang; Fen Yang; Yuliang Sun; Lidan Niu; Yakun Ren; Hongmei Wang; Yanan He; Jiang Du; Jun Yang; Juntang Lin
Journal:  Stem Cell Res Ther       Date:  2020-08-08       Impact factor: 6.832

Review 6.  The key roles of cancer stem cell-derived extracellular vesicles.

Authors:  Chaoyue Su; Jianye Zhang; Yosef Yarden; Liwu Fu
Journal:  Signal Transduct Target Ther       Date:  2021-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.